

Emetic Potential of Individual Agents

Minimal Emetogenic potential	Low emetogenic potential	Moderate emetogenic potential	High emetogenic potential
<ul style="list-style-type: none"> • Alemtuzumab • Alpha interferon • Asparaginase (intramuscular [IM] or intravenous [IV]) • Bevacizumab • Bleomycin • Bortezomib • Dasatinib • Dexrazoxane • Fludarabine • Gemtuzumab • ozogamicin • Mercaptopurine (oral) • Methotrexate $\leq 50 \text{ mg/m}^2$ • Nelarabine • Rituximab • Sorafenib • Temsirolimus • Thalidomide • Thioguanine (oral) • Vinblastine • Vincristine • Vinorelbine 	<ul style="list-style-type: none"> • Amsacrine • Busulfan (oral) • Cytarabine $\leq 200 \text{ mg/m}^2$ • Etoposide • Fludarabine (oral) • Gemcitabine • Intrathecal therapy • Methotrexate $>50 \text{ mg/m}^2$ to $<250 \text{ mg/m}^2$ • Mitomycin • Mitoxantrone • Thiotepa $<300 \text{ mg/m}^2$ • Topotecan • Vorinostat 	<ul style="list-style-type: none"> • Arsenic trioxide • Busulfan $>4 \text{ mg/kg/day}$ • Carboplatin • Carmustine $\leq 250 \text{ mg/m}^2$ • Clofarabine • Cyclophosphamide • Cytarabine $>200 \text{ mg/m}^2$ to $<3 \text{ g/m}^2$ • Dactinomycin (Actinomycin D) • Daunorubicin • Doxorubicin • Epirubicin • Etoposide (oral) • Idarubicin • Ifosfamide • Irinotecan • Lomustine • Melphalan $>50 \text{ mg/m}^2$ • Methotrexate 250 mg/m^2 to $<12 \text{ g/m}^2$ • Procarbazine • Temozolomide (oral) • Thiotepa $\geq 300 \text{ mg/m}^2$ • Vinorelbine (oral) 	<ul style="list-style-type: none"> • Carmustine $>250 \text{ mg/m}^2$ • Cisplatin • Cytarabine $3 \text{ g/m}^2/\text{dose}$ • Dacarbazine • Methotrexate $\geq 12 \text{ g/m}^2$